“Hacking the software of life”
– Dr Tal Zaks, Moderna’s Chief Medical Officer.
Messenger RNA vaccines are being touted as the way forward in combating the CCP virus, yet permanent, gene-altering technology, fast-tracked to become the first Covid-19 vaccine widely available for use, is deeply concerning, considering that this experimental vaccine with potentially far-reaching consequences has had little to no testing on Humans.
Updated; 20/Jan 2021
As the CCP virus finally became self-evident to the West (around 11/Mar), global markets tanked in unison, including even the traditional safe haven – gold. Obviously these were unprecedented times.
With the world soon to be on lock-down until a ‘magic bullet’ to the virus was found, it was obvious that bio-tech was the sector to now focus on.
From a watch list, one company soon stood out – Moderna Inc. [MRNA:NASDAQ].
Of the 80+ companies in the vaccine race, Moderna would continue to post gains on a daily basis, often double digits, and sometimes in complete defiance of the IBB biotech index.
Moderna initially reached unicorn status ($1B+ valuation) in 2012 in just two years, and in May 2020, Moderna was valued at $30 billion, despite that none of its therapeutics have been brought to market, and none of it’s mRNA molecules have ever reached human clinical trials (prior to the currently fast-tracked mRNA-1273 vaccine).
In fact, several had failed due to negative side-effects, yet Moderna’s seeming ‘immunity’ to the current market volatility caused by the CCP virus, as well as it’s history of defying financial gravity, prompted me to take a closer look.
Who is Moderna Inc.?
Moderna Inc. is an American clinical stage Bio-tech company out of Cambridge, MA. Founded 2010 by stem cell biologist Derrick Rossi, who was hailed by Time magazine as one of the 100 most influential people of 2011 for a novel stem-cell treatment.
Soon after the then named ‘Moderna Therapeutics’ was formed, Rossi approached others to co-invest, and was introduced to Bob Langer, MIT scientist and entrepreneur, a name that is seemingly always in the shadows of biotech, and “the common denominator” in several coronavirus efforts. Boston has always said; that if you want to start a biotech company, you must first see Robert Langer.
In 2011, the CEO of Flagship Ventures (now Flagship Pioneering), Noubar Afeyan, brought in controversial European pharma sales and operations executive Stéphane Bancel, as CEO.
“Bancel had no experience running a drug development operation…he’d spent most of his career in sales and operations, not science… He is listed as a co-inventor on more than 100 of Moderna’s early patent applications, unusual for a CEO who is not a PhD scientist.”thrillist
So with the support of Flagship Venture Labs, Rossi, Langer, Afeyan, and Chien gathered together to form Moderna Therapeutics. The concept of the company’s name comes from the abbreviation of ‘Modified RNA’ – Moderna.
Moderna has partnership’s with a who’s who list major players in the experimental vaccine field, including the Defense Advanced Research Projects Agency (DARPA), The Bill and Melinda Gates foundation (BMGF), (BARDA), Merck & Co., and of course, the National Institute of allergies and Infectious Diseases (NIAID), headed up by none other than Dr Anthony Fauci.
Fortuitous Funding & Financing;
The Pentagon’s Defense Advanced Research Projects Agency (DARPA) played an important role in helping Moderna establish its mRNA platform, awarding the biotech a contract for $25 million in October 2013.
This marked the start of DARPA’s continued, quiet interest and financial support into Moderna.
This grant is part of a DARPA program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.moderna
Earlier that year, in March 2013, Moderna, a small start-up with just 25 employees, signed a staggering $240 million (cash payment) partnership with UK pharmaceutical giant AstraZeneca. “It was the most money pharma had ever spent on drugs that had not yet been tested in humans.” – NY Times.
It was reported that for AstraZeneca, the signing of this agreement was largely due to the company’s situation at the time; AstraZeneca’s several key drug patents were about to expire, and due to the failure of several clinical trials, AZ decided to reorganize their R&D business, and lay off more than 1600 scientists.
The signing of the agreement became a turning point for Moderna, and soon the investment field’s gold rush into the biotech began. It seems that suddenly every investment institution wanted a piece of Moderna.
In January 2014, Moderna and Alexion Pharmaceuticals entered a $125 million deal for ‘orphan diseases’ in need of therapies. Alexion paid Moderna $110 million for 10 product options to develop rare-disease treatments, using Moderna’s mRNA therapeutics platform.
In 2016, Bancel told an audience of J.P. Morgan investors that the work with Alexion would shortly enter human trials. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials that year. Bancel failed to mention the lack of efficacy in trials of the project so far. The healthcare conference announced $350 million in new investment into Moderna.
In 2016, the Biomedical Advanced Research and Development Authority (BARDA) announced up to $126 million in grant funding for Moderna to develop a Zika virus vaccine, and since then, Moderna’s RNA vaccine program has received $100 million in funding from the Bill and Melinda Gates Foundation.
The Gates Foundation has since poured millions directly into both Moderna’s and Inovio’s CCP virus RNA vaccine efforts.
In July 2017, Alexion stopped the cooperation with Moderna, and the program with Alexion was scrapped, as the animal trials showed that Moderna’s treatment (ALXN1540) would never never prove safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project.
After the failed trials, Moderna moved to focus on mRNA vaccines given that mRNA will always stimulate a level of antibody development in subjects, efficacy issues aside. The change in strategy had risk given the materially lower margins of vaccine development (called “loss-leaders” by some Moderna employees), with some senior employees and industry experts questioning the future viability of the company.
Founder, Derrick Rossi, left the company shortly after.
The choice to prioritize vaccines came as a disappointment to many in the company, according to a former manager. The plan had been to radically disrupt the biotech industry, the manager said, so “why would you start with a clinical program that has very limited upside and lots of competition?”
Considering Bancel’s mercenary-like history in the pursuit of profit, yet deciding to take the company in seemingly the opposite direction, I think it’s a safe assumption that Moderna was now being funded by a higher power, one focused on the potential in mRNA, specifically delivered via vaccines.
In early 2015, Moderna announced the completion of a new round of financing of $450 million from a range of investors, including DARPA. In February 2016, an op-ed in Nature, criticized Moderna for not publishing any peer-reviewed papers on its technology, unlike most other emerging and established biotech companies, and compared its approach to that of the controversially failed fraudulent medical company, Theranos.
Bancel had repeatedly promised that Moderna’s new therapies will change the world, but the company refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists.
A former Moderna scientist told Stat: “It’s a case of the emperor’s new clothes. They’re running an investment firm, and then hopefully it also develops a drug that’s successful“.
However, by this stage in Moderna’s timeline, I suspect the lack of published results may be more a secrecy driven agenda, more than simply having no proof of efficacy. For a company to attract such high levels of investment without publishing anything to attract investors is peculiar.
In September 2018, Thrillist published article titled, “Why This Secretive Tech Start-Up Could Be The Next Theranos”, criticizing Moderna’s reputation for secrecy and the absence of scientific validation or independent peer-review of its research, though having the highest valuation of any U.S. private biotech company at more than $5 billion.
In 2018 the company re-branded as “Moderna Inc.”, and with the ticker symbol; MRNA, moved to go public on the US NASDAQ market. It was the largest biotech initial public offering in history, raising $621 million (27 million shares at $23 per share) on the NASDAQ, and implying an overall valuation of $7.5 billion for the entire company. It’s IPO valuation left some investors scratching their heads as to how the company’s vaccine-heavy pipeline and lack of applicable results could justify such a number.
The year-end 2019 SEC filings showed that Moderna had accumulated losses of $1.5 billion since inception, with a loss of $514 million in 2019 alone, and had raised $3.2 billion in equity since 2010. Moderna [MRNA:NADAQ] is currently valued at $25 Billion dollars.
Dr. Joseph Bolen, who served as Moderna’s chief scientific officer and president of research and development from 2013 to 2015, believes it was reasonable to give Moderna a shot, but was puzzled by BARDA’s massive April 2020 allocation of up to $483 million, a new company record, calling it “a big bet.”…”I don’t know what their thinking was,” he said. “Why so much? … I just don’t know. When I read that, I was pretty amazed.”
“It’s a big bet for the ten-year-old company, which currently has 24 products in its pipeline—but nothing yet on the market. The biotech sports a huge market cap of $17.5 billion, but it posted a net loss of $514 million on revenues of just $60 million last year. And most of that incoming cash came from government grants and research collaborations with big pharmaceutical companies.”Forbes, may 8
Moderna has never put a single product into the marketplace.
Last year, it lost $514 million. It took in $60 million. But it’s somehow worth $25 billion+.
A timeline of Moderna’s funding can be viewed here.
Moderna announced in a Jan. 23rd press release: “Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus”.
Moderna is also funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
From CEPI’s website; “CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum.”
Davos is an exclusive four-day annual event. It’s an opportunity for the world’s most influential people to meld minds over the world’s economic and political challenges, and, more importantly, to network. The event is named after its host city, in Switzerland, Davos.
The same press release also states in the T&C’s, under the section titled; ‘Special Note Regarding Forward-Looking Statements’ – “the fact that there has never been a commercial product utilizing mRNA technology approved for use”.
What in the world could possibly go wrong?
One way to find out is to unleash it on millions of people, stand back, and see.
Lucrative Partnerships, Influence, & Conflicts of Interest;
It’s completely correct to say that NIAID will reap a profit on the Moderna/NIAID vaccine. There are 6 NIAID scientists who work for Dr. Fauci, each of whom would get $150,000/year indefinitely as their reward. So that’s $900,000 to his subordinates every year in perpetuity.”Mary Holland, General Counsel, Children’s Health Defense
In May 2020, board member Dr. Moncef Slaoui resigned from the company to become Chief Scientist for the Trump administration’s “Operation Warp Speed”, a group designed to accelerate the development of a vaccine for the coronavirus. Slaoui continued to hold more than $10 million in stock options in Moderna while in his new role, while the Federal government invested $483 million in the company to assist in coronavirus vaccine trials.
Also in May, on the 18th, 2020, Moderna announced it was making progress with its coronavirus vaccine, and the company’s stock price rose 30%.
That same day, CFO Lorence Kim exercised stock options for $3 million and immediately sold it for $19.8 million, collecting $16.8 million.
The next day, chief medical officer Tal Zaks did the same for $1.5 million, and immediately sold it for $9.77 million, triggering a profit of $8.22 million. Both of these executives were using automated insider trading plans known as 10b5-1 plans – a legal loophole for insider trading.
Matt Egan and Chris Isidore wrote an excellent article discussing these sales in more detail, and a list of recent insider transactions can for Moderna can be viewed here.
Lorence Kim, also made stock sales prior to the vaccine news. On May 15, just days before the results were announced, Kim sold 20,000 shares of stock worth $1.3 million. After Noubar Afeyan, and Robert Langer, CEO Bancel is the largest individual shareholder in the company.
Not a conflict of interest, but noteworthy; the value of board member Bob Langer’s 3.2% holding, including stock options, rose to $934.3 million on May 18, 2020, as the shares surged 20% to a record $80 each.
Langer would be at least the third individual with Moderna holdings topping $1 billion, joining Chief Executive Officer Stephane Bancel and Harvard University professor Timothy Springer.
There is also a great deal of influence, and in-house deals going on in and around Moderna by players such as Bill Gates, Anthony Fauci, the National Institute of Health (NIH), and the US Government.
Robert F Kennedy Jr., on the Thomas Paine Podcast, detailed an apparent agreement between the National Institute of Health (NIH) and the Bill Gates-backed pharmaceutical company Moderna, which has the best chance of securing lucrative contracts for a national CCP virus vaccine. The NIH is the key player in deciding which vaccines are approved, and the NIH and government would profit wildly if the Gates-backed pharma play Moderna Inc. gets the green light. And it since has.
A June 25th article by Axios, titled; ‘The NIH claims joint ownership of Moderna’s coronavirus vaccine’ details that the National Institutes of Health may own intellectual property that undergirds the mRNA-1273 vaccine being developed by Moderna, according to documents obtained by Axios and an analysis from Public Citizen.
Moderna’s Strict Secrecy Policy;
Moderna was often, if not always referred to as a mystery in the financial and medical press last decade. For a biotech garnering that level of attention and funding, you would expect them to be publishing results, and consistently. Yet Moderna kept everything under wraps. Always.
I suspect that Moderna has had all the funding it needed from US Government agency DARPA by early to mid 2010’s, as well as the Gates’ Foundation, and simply didn’t need to attract new investment, which after all, often comes with scrutiny.
Large investors were granted a peek at a small section of MRNA’s work, but other than that, it was a case of “just trust us”. Articles in the science press sometimes refer to the company as “mysterious” or “secretive.”
Moderna has had so many investors clamoring to get in over the years that it can afford to turn away any who ask too many questions, in fact it’s so secretive that some job candidates have to sign nondisclosure agreements before they come in to interview.
Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.
A Caustic Work Culture;
A 2016 STAT investigation found that the company’s caustic work environment has for years driven away top talent and that behind its obsession with secrecy, there are signs Moderna has run into roadblocks with its most ambitious projects.
Moderna lost the director of two chemical departments within one year, and then the chief science officer and the director in charge of drug production quickly left. Within just a year, the heads of the Oncology, Chemistry, Rare Diseases, and Cardiovascular departments also left.
Apart from scientific research or personnel management problems, there are few other reasons to leave. If Moderna’s technology really changed the entire biomedical industry, why would so many people choose to resign?
Stéphane Bancel built a culture of recrimination at Moderna, former employees said. Failed experiments have been met with reprimands and even on-the-spot firings. They recalled abusive emails, dressings down at company meetings, exceedingly long hours, and unexplained terminations.
At least a dozen highly placed executives have quit over the years, including heads of finance, technology, manufacturing, and science. In 2015, respected leaders of Moderna’s cancer and rare disease programs both resigned, even though the company’s remarkable fundraising had put ample resources at their disposal. Each had been at the company less than 18 months, and the positions remained vacant for 12 months.
The company improved its margins under Bancel’s tenure, and he developed a reputation as a stern manager who got results, according to an equities analyst who covered bioMérieux at the time;
“He doesn’t suffer fools lightly,” the analyst said, speaking on condition of anonymity to comply with company policy. “I think if you’re underperforming, you’ll probably find yourself looking for another job.”stat
Moderna and The Gates (of Hell);
“One of the questions I get asked the most these days is when the world will be able to go back to the way things were in December before the coronavirus pandemic. My answer is always the same: when we have an almost perfect drug to treat COVID-19, or when almost every person on the planet has been vaccinated against coronavirus.”Bill Gates – April 30, 2020
The Bill and Melinda Gates Foundation’s (BMGF) backing of DNA and RNA vaccines is significant, given that Bill Gates, a billionaire with unparalleled influence and control over global healthcare policy, recently asserted that the best options for a CCP virus vaccine are mRNA vaccines, despite the fact that they have never before been approved for use in humans.
Yet, thanks to the U.S. government’s emergency authorizations activated due to the current crisis, both Moderna’s and Inovio’s testing for these vaccines has skipped animal trials and gone straight to human testing. They are also set to be fast-tracked for widespread use in a matter of months. Moderna’s clinical trial in humans began in mid-March, and their vaccine, which is being jointly developed with the government’s National Institute of health (NIH), followed by Inovio’s in the beginning of April. They are both Gates’ favorites to due to their mRNA vaccines.
Recently, Moderna Inc. was praised in an op-ed published on Bill Gates personal blog, ‘Gates Notes‘. Moderna have a ‘strategic partnership‘ with BMGF, and the Gates have given millions to Moderna through the Bill and Melinda Gates Foundation (BMGF), though his piece didn’t mention the company by name.
It’s worth noting that Inovio also has an infamous record of undelivered promises. Citron Research has recently come out (PDF) against Inovio, labeling its COVID-19 vaccine claims as Theranos-like. Theranos was a sham medtech company that promised a simple blood test that could diagnose multiple diseases. The firm’s attack claimed that Inovio developed a vaccine in just three hours and “under the same scientific team that has spent decades deceiving investors.”;
It’s been over 40 years since Inovio was founded, yet the company has NEVER [sic] brought a product to market, and all the while insiders have enriched themselves with hefty salaries and large stock sales.” Citron said that Inovio shareholders have been “Theranosed” by the company.Citron research April 27, 2020
In addition, AstraZenecka also had a partnership with Inovio pharmaceuticals at one stage, and similarly canceled it as they did with Moderna, due too many broken promises.
Almost one-fourth (20/83) of the vaccines listed by the World Health Organization (WHO) as COVID-19 “candidate vaccines” as of April 23, including two of the leading contenders, are DNA (Inovio) or mRNA (Moderna) vaccines (see table).
With billions in funding from the U.S., partnerships with the WHO and other UN factions, buying the media, universities, scientists and researchers, big pharma, and hundreds of NGOs, Gates rules the healthcare industry in its entirety. The WHO is only one part of the equation, and they need to be cutoff immediately as well, especially considering Gates is the WHO’s second largest source of funding, some $3.5 billion to date.
What is messenger RNA & Moderna’s mRNA-1273 vaccine?
m – messenger / RNA – RiboNucleic Acid.
Here’s the idea: Instead of producing protein drugs using genetically engineered bacteria in dedicated manufacturing plants—the dominant biotech model of the past 30 years—why not enable the human body to produce its own protein drugs, on demand?
Researchers began tinkering in the mid-1990s with nucleic acid vaccines, which include DNA vaccines and messenger RNA (mRNA) vaccines.
As a form of gene therapy, both represent a significant departure from classical vaccines. Whereas the latter introduce a vaccine antigen to produce an immune response, nucleic acid vaccines instead send the body instructions to produce the antigen itself.
After the mRNA, a chemical messenger that contains instructions for making proteins, “code” is injected into the body, it instructs the machinery in your cells to produce particular proteins. Your body then becomes a vaccine factory, producing parts of the virus that trigger the immune system.
Although it may sound simple to use mRNA to express proteins into cells, there are several obstacles in practical applications. For example, cells sense the invasion of foreign mRNA and activate the body’s innate immune system to degrade these foreign nucleic acids. This is the body’s mechanism for self-protection to prevent cells from being manipulated by intruders.
Messenger RNA is a technique that was abandoned by several large pharmaceutical and biotech companies over the years, as they were unable to overcome the dangerous side-effects of getting RNA into cells.
As of May 2020, no mRNA drug has been approved for human use, other than Moderna’s government fast-tracked CCP virus vaccine; mRNA-1273.
In order to protect mRNA molecules from the body’s natural defenses, drug developers must wrap them in a protective casing. For Moderna, that meant putting its Crigler-Najjar therapy in nanoparticles made of lipids. But dose too little, and you don’t get enough enzyme to affect the disease; dose too much, and the drug is too toxic for patients. Nanoparticles can lead to dangerous side effects, especially if a patient has to take repeated doses over months or years.
The idea of using mRNA to ask the human body to read the instructions and manufacture the viral proteins is not new. Researchers almost two decades ago demonstrated that externally supplied mRNA is translated into the encoded protein. However, mRNA is not a very stable molecule, which prevented those mRNA vaccines from becoming a reality.
Also, if gene therapy ‘chooses’ certain types of viruses as vectors, it can actually cause fatal side effects or induce patients to develop leukemia.LINK
However, since at least last year, Moderna has sought to resolve this issue by adding “nano-particles” to its mRNA vaccine, a modification financed by the Defense Advanced Research Projects Agency (DARPA).
It’s important to note that DARPA has been very interested in healthcare, specifically vaccines since 2010. It was also around the same time that the Bill and Melinda Gates Foundation also began heavily funding DNA and RNA vaccine research.
mRNA itself is also very unstable and difficult to develop into drugs. A few years after it’s inception, scientists discovered that the mRNA synthesized in the lab could trigger an immune response after injection, resulting in a more dangerous inflammatory response, than the disease being treated.
Several workarounds for this issue have been proposed, including vaccines where the genetic material (RNA or DNA) “self-amplifies.” However, the workaround of choice to this lack of immune response and other obstacles for DNA/RNA vaccines is the incorporation of nanotechnology into these vaccines. As a result, the use of nanoparticles as the carriers for the genetic material in these vaccines has been widely promoted and studied, as well as touted as the best way to improve their stability, increase their targeted delivery ability and enhance the immune response they provoke.
DARPA often frames the controversial technologies it develops as being developed to mainly advance medicine and healthcare, whereas evidence suggests otherwise. DARPA has a long history in bringing nightmares into reality; another long-standing DARPA program, is known as “Living Foundries.” According to DARPA’s website, Living Foundries;
“…aims to enable adaptable, scalable, and on-demand production of such molecules by programming the fundamental metabolic processes of biological systems to generate a vast number of complex molecules that are not otherwise accessible. Through Living Foundries, DARPA is transforming synthetic biomanufacturing into a predictable engineering practice supportive of a broad range of national security objectives.DARPA
When the genomic sequence of the virus was first uploaded by Chinese scientists on January 11 to GISAID, the global influenza strain public database, the Moderna team had a vaccine design ready within 48 hours.
It shipped a batch of its first vaccine candidate to the National Institutes of Health (NIH) for a phase one study just 42 days after that. On March 16th, Moderna’s mRNA vaccine, which consists of an entirely untested gene editing technology to initiate immunity to disease, was injected into humans for the first time.
That’s lightning fast. Vaccines typically take years (or in some cases, decades) to develop, but it’s not fast enough for Bancel. “Every day we’re losing lives; we really believe that every day matters,” he says.
Fauci is also moving forward, without waiting for the green light from trials or the US Government. In an appearance on NBC’s Today Show, Fauci was asked whether he thought it was “in the realm of possibility” to have a potential vaccine ready for wide distribution by January;
“In other words, you don’t wait until you get an answer before you start manufacturing. You at risk — proactively — start making it, assuming it’s going to work,” Fauci said. “And if it does, then you can scale up and hopefully get to that timeline.”Anthony Fauci, NPR
So is messenger RNA safe or not?
The TL;DR is; we simply don’t know.
And that’s reason enough not to go down this alley.
With the effects having the potential to permanently change our species DNA in ways we can’t possibly predict in the long-term, it’s the ultimate gamble. For a flu shot.
In a 2017 TED Talk, two years after joining Moderna, Moderna’s Chief Medical Officer, Dr. Tal Zaks, spoke at length about how he views mRNA vaccines and their functionality, including those he produces at Moderna. In a speech entitled “The disease-eradicating potential of gene editing,” Zaks’ describes Moderna’s mRNA products as, making permanent edits to human genes, clashes with often touted claims that the genetic material in mRNA vaccines “degrade” over time and do not permanently alter human genetics like DNA vaccines.
At the beginning of his talk, Zaks states that Moderna and similar companies;
“are actually hacking the software of life and that it’s changing the way we think of and treat disease.” He describes mRNA as “critical information that determines what a cell will actually do” and then states that, if one could “introduce a line of code or change a line of code” in a person’s genome, that has “profound implications for everything.”Dr Tal Zaks
He then falsely claims that Moderna’s products at the time were proven to “work in people” yet the company was never able to convince the federal government to license its mRNA vaccines for human use due to their lack of effectiveness. Excluding having it’s CCP virus vaccine, mRNA-1273, fast-tracked in 2020.
Interestingly, the recommended talk on the ‘TED talks’ website that immediately follows Zak’s talk is titled; ‘Gene Editing Can Now Change an Entire Species – Forever‘, by Jennifer Kahn.
She explains how this exact technology can result in the entire eradication of a species, depending on what ‘message’ the RNA inserted into the human body has for our cells. And mRNA is a long way from being an exact science.
High stakes, wouldn’t you say?
(She goes on to state shortly after that CRSPR technology can not be used to engineer viruses. Whether the tech evolved in the 12 months after the talk was given, or she got that one ‘accidentally’ wrong is unclear.)
“…better understanding of [RNA] vaccine adverse effects is need – these can include inflammation and autoimmune reactions”The PHG Foundation at the University of Cambridge
Autoimmune reactions — the human immune system attacks healthy elements and processes of the body, or in other words, the body goes to war with itself.
mRNA approaches seem to attract researchers with a highly mechanistic view of human beings. The CEO of Moderna, Bancel, describes mRNA approaches—which use “custom-built” strands of mRNA to “turn the body’s cells into ad hoc drug factories”—as being “like software: You can just turn the crank and get a lot of products going into development.” Likewise, the journal Nature enthuses that the approach “allows rapid refinement with almost limitless combinations of derivatives.”
It’s worth noting that the FDA was aware of vaccine technology outpacing our ability to predict adverse events as far back as 1999 in their publication “The Pink Sheet” [PDF], yet they seem to be OK with rushing through largely untested on humans mRNA in vaccines in 2020.
Info graphic on ; ‘Engineering The Messenger‘ from Science.
It’s certainly troubling that media coverage of DARPA’s efforts and the efforts of Moderna and Inovio have thus far not included critical reporting regarding the different branches of DARPA’s research that has produced the technology involved in creating these vaccines, leaving little room for public scrutiny of their safety, efficacy and their potential for unintended effects on human genetics.
This is particularly alarming given that, over the past several weeks, efforts have been taking shape in many countries to enforce mandatory vaccinations once a Covid-19 vaccine becomes available. In some countries, it appears likely that the Covid-19 vaccine will not be made mandatory per say, but will be required for those who wish to return to any semblance of “normalcy” in terms of public gatherings, working certain jobs, leaving one’s home for longer periods of time and so on.
In this case a Certificate Of Vaccination I.D. (C.O.V.I.D?) will be required, and of course Bill Gates has just the thing – Quantum dot tattoos.
The QDot tattoos are a story within themselves, so I’ve detailed it in a separate post, but they require an enzyme called ‘Luciferase’ to work.
Can’t make this stuff up.
Gates’ affinity for Moderna may owe to the fact that Moderna’s co-founder, MIT’s Robert Langer, is a Gates associate, whose lab developed the Gates-funded “quantum dot ‘tattoo’” vaccine identification marker that is “visible using a special smartphone camera app and filter”, and was described by Science Alert as “a low-risk tracking system.”
Another Langer-Gates partnership is a “birth control microchip” inserted to the body that releases contraceptives and can be turned on and off wirelessly.
Given that the stage has already been set for mandatory vaccinations that will be “distributed” throughout the U.S. by the military, and by other means globally, now is the time to vigorously raise awareness about the Moderna vaccine’s gravely under-reported ability to “hack the software of life” in ways that could harm public health.
So what’s Going On?
The COVID vaccine Moderna is working on utilizes brand new RNA technology. No RNA drug or vaccine product has ever been certified for public use.
Other companies have tried and failed, mainly because safety was a serious problem.
mRNA has already been injected into the human race by Moderna as of March 16, 2020.
Moderna, backed by Gates, is partnering with the National Institute of Allergy and Infectious Diseases (NIAID), the federal agency headed up by Tony Fauci.
How many red flags do you need?
Will a vaccine come to fruition from all of this? Will they achieve their trillion-dollar dream of the Global Fund 2.0, where they can pump the world full of another cocktail of their choice while thieving billions upon billions in taxpayer dollars to fund it?
Further reading; CORONAVIRUS GIVES A DANGEROUS BOOST TO DARPA’S DARKEST AGENDA. – Whitney Webb.